Brief: Actinium Pharmaceuticals Says Actimab-A Being Studied In A Phase 1 Combination With Bcl-2 Inhibitor In Patients With Relapsed Or Refractory AML
26/02/2020 12:49
Feb 26 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM ANNOUNCES ACTIMAB-A PLUS 7+3 COMBINATION TRIAL
FOR
NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS
* ACTINIUM PHARMACEUTICALS - ACTIMAB-A BEING STUDIED IN A
PHASE 1
COMBINATION WITH BCL-2 INHIBITOR IN PATIENTS WITH RELAPSED OR
REFRACTORY AML
Source text for Eikon: ID:nPn21Lx3ta
Further company coverage: ATNM.A
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities